Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for ExpreS2ion Biotech Holding AB's Net Cash per Share or its related term are showing as below:
OSTO:EXPRS2'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.67 Med: 3.68 Max: 106
Current: 0.71
During the past 10 years, the highest Price-to-Net-Cash Ratio of ExpreS2ion Biotech Holding AB was 106.00. The lowest was 0.67. And the median was 3.68.
OSTO:EXPRS2's Price-to-Net-Cash is ranked better than 95.48% of 774
companies
in the Biotechnology industry
Industry Median: 4.91
vs OSTO:EXPRS2: 0.71
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
ExpreS2ion Biotech Holding AB Net Cash per Share Related Terms
ExpreS2ion Biotech Holding AB Net Cash per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ExpreS2ion Biotech Holding AB Net Cash per Share Chart
OSTO:EXPRS2 vs VRTX, REGN, MRNA: Net Cash per Share Comparison
For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ExpreS2ion Biotech Holding AB Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where ExpreS2ion Biotech Holding AB's Price-to-Net-Cash falls into.
ExpreS2ion Biotech Holding AB Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) has a Net Cash per Share of kr0.77 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on ExpreS2ion Biotech Holding AB and its competitors. According to the industry distribution chart, ExpreS2ion Biotech Holding AB ranks #35 out of 774 companies in the Biotechnology industry, placing it in the top 4.5%.
Is ExpreS2ion Biotech Holding AB's Net Cash per Share too high?
ExpreS2ion Biotech Holding AB's current Net Cash per Share is kr0.77. Based on the distribution chart, ExpreS2ion Biotech Holding AB ranks #35 out of 774 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ExpreS2ion Biotech Holding AB ranks #35 out of 774 companies for Net Cash per Share. This places ExpreS2ion Biotech Holding AB in the top 5% of its industry — outperforming the majority of peers. The industry median Net Cash per Share is 4.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 4.91, based on 774 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on ExpreS2ion Biotech Holding AB and its competitors. For the Biotechnology industry, the median Net Cash per Share is 4.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ExpreS2ion Biotech Holding AB's current Net Cash per Share is kr0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) is currently considered Possible Value Trap. The stock's GF Value™ is kr2.96, compared to a current price of kr1.33 — trading 55.2% below its estimated fair value. The current Net Cash per Share is kr0.77. ExpreS2ion Biotech Holding AB's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (OSTO:EXPRS2), the current Net Cash per Share is kr0.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Overvalued in 2026?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued.
The current stock price of kr1.33 is trading 55.2% below its estimated GF Value™ of kr2.96.
GuruFocus considers ExpreS2ion Biotech Holding AB to be Possible Value Trap.
Key valuation signals for OSTO:EXPRS2:
Net Cash per Share: kr0.77
GF Value™: kr2.96 vs. price of kr1.33 (55.2% below fair value)
No single metric tells the full story. See the OSTO:EXPRS2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
41GF Score
Get the complete analysis for OSTO:EXPRS2
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EXPRS2 has been successfully added to your 
